ConocoPhillips (COP)vsNovo Nordisk A/S (NVO)
COP
ConocoPhillips
$113.87
-0.88%
ENERGY · Cap: $139.96B
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 452% more annual revenue ($327.80B vs $59.38B). NVO leads profitability with a 37.2% profit margin vs 12.3%. COP appears more attractively valued with a PEG of 1.14. NVO earns a higher WallStSmart Score of 74/100 (B).
COP
Buy56
out of 100
Grade: C
NVO
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.4%
Fair Value
$73.94
Current Price
$113.87
$39.93 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.1%
Generating 1.3B in free cash flow
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
Revenue declined 5.3%
Earnings declined 20.2%
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : COP
The strongest argument for COP centers on Market Cap, Price/Book, Operating Margin. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : COP
The primary concerns for COP are Revenue Growth, EPS Growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
COP profiles as a declining stock while NVO is a growth play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.35 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 56/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ConocoPhillips
ENERGY · OIL & GAS E&P · USA
ConocoPhillips is an American multinational corporation engaged in hydrocarbon exploration. It is based in the Energy Corridor district of Houston, Texas.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other OIL & GAS E&P Stocks
Want to dig deeper into these stocks?